An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Ryght AI traveled down country roads to find the newest member of its growing clinical trial site collection. | Ryght AI ...

Heartflow has pumped up its IPO ambitions, raising its proposal into the vicinity of $300 million. | After first pricing its ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic.  | Alltrna, the preclinical Flagship ...

The Trump administration has broken the law by withholding funds that Congress had allocated to the National Institutes of Health (NIH), according to the Government Accountability Office (GAO).

The Department of Health and Human Services (HHS) has announced a plan to end mRNA vaccine work funded by the Biomedical ...